$JPM will be releasing its 1Q24 financial results on the 12th of April 2024.

For 1Q24E, the consensus estimates JPM to deliver an EPS of 4.23/share (vs 3.41/share in 1Q23) and revenue of USD41.8bn (vs USD36.1bn in 1Q23).

This could mean that JPM earnings are expected to be front-end loaded, still capturing strong earnings growth in 1H24 from the high-interest rates environment before the Fed starts to cut rates in 2H24.

Read more here: https://intvestor.substack.com/p/jp-morgan-chase-and-co-part-2-coming

This is Part 1 of a company deep dive on J.P. Morgan $JPM.

Over the past five years, JPM share price generally moves in line with the S&P 500. However, during periods of a market uptrend, JPM tends to outperform the index.

On the other hand, during periods of a market downtrend, JPM tends to underperform the S&P 500.

Read it here: https://open.substack.com/pub/intvestor/p/jp-morgan-chase-and-co-part-1-higher?r=lbdnn&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

This is Part 2 of a deep dive on Visa Inc. The stock is currently trading at 30.1x which is along the line of its five-year historical forward mean PE. This seems to be fairly valued.

Even then, the share price was trading along the +1SD above its five-year forward mean PE of 35-40x between 2019-2021. In my opinion, there could be some room to grow further in the near term.

What do you think of Visa's valuation? $V

Read the full article here: https://shorturl.at/gsuD6

Our portfolio review of the US market as of Feb 2024 -

+60% returns after 5 months of inception

Read the full article here: https://shorturl.at/CISW7

$NVDA $ULTA $SMCI $JPM $NVO $V $ARM $AMPH

Started 2024 with some good gains from the stock market (+29% MoM). Riding on the excitement of the strong FY23 financial results. 📈

$ASML $TQQQ $NVDA $NVO $JPM $VGIT

Read it here: https://intvestor.substack.com/p/jan-2024-portfolio-review-29-mom

This is Part 2 of a company deep dive on Novo Nordisk $NVO which includes an analysis of its balance sheet, cash flow, earnings forecasts and my valuations.

Currently trading close to +3SD above its five-year forward mean PE, the share price seems overbought and may be due for a mean reversion in the near term.

What do you think? Does it still have legs?

Read it here: https://intvestor.substack.com/p/novo-nordisk-as-part-2-declining

This is Part 1 of a company deep dive on Novo Nordisk A/S $NVO.

In this post, I'll be looking at company operations, key drivers and key risks.

A little late in the year but here's a breakdown of how our investment portfolio performed in 2022 and 2023 📊

Read the full article here: https://open.substack.com/pub/intvestor/p/2023-and-2022-portfolio-review?r=lbdnn&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

$ASML $NVO $TQQQ $VOO

This week, I share a compilation of the basic financial ratios to use when analysing company's financial statements.

$LVMHF Birkenstock $VGIT